Purpose-built for physicians Many people remain excluded from GLP-1 clinical trials for weight loss Key takeaways: Up to 33.1% of adults eligible for GLP-1 receptor agonist treatment met trial exclusion criteria
Basic Life of the Party Member Pricing $136 | $160 Rehydrate and relieve headache, body aches, and queasiness from overindulgence
healthy red blood cell formation
Cardiac protection: Unlike BPC-157's gastric origins, TB-500 has been studied particularly for cardiac applications, showing potential for heart tissue repair
Share this Article Back to Home Page
Cyclic Heptapeptide Lactam-Bridged Macrocycle -MSH Analogue Reported Pharmacology (Literature, Neutral) Reported Melanocortin receptor agonism Non-selective MC1R / MC3R / MC4R / MC5R agonist Molinoff and colleagues (Ann N Y Acad Sci 2003) reported: PT-141, a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system. Reported as a neutral pharmacology statement in the academic record
